Jun 15, 2016

GSK, Telethon and OSR gene treatment for ADA-SCID approved

GlaxoSmithKline (GSK), Fondazione Telethon (Telethon) and Ospedale San Raffaele (OSR) recently announced that the European Commission has approved Strimvelis, the first ex-vivo stem cell gene therapy to treat patients with ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency). For more information please see:

http://www.gsk.com/en-gb/media/press-releases/2016/strimvelistm-receives-european-marketing-authorisation-to-treat-very-rare-disease-ada-scid/



World PI Week
Donations
banner2
IPOPI would be grateful for any support to the important work for primary immunodeficiencies.

Read all

Contact
Executive Director: Johan Prevot
Email: johan@ipopi.org
Tel/Fax: +351 21 407 5720
UK office
Firside Main Road Downderry
Cornwall PL11 3LE
United Kingdom

Tel: +44 1503 250 668
Fax: +44 1503 250 961
E-mail: info@ipopi.org
IPOPI is a charity registered in the UK.
Registration No. 1058005